Audit Review Table

WellCare Health Insurance of Illinois, Inc. dba WellCare of Kentucky, Inc. (Org ID: 8732, SubID: 11095, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2013

This submission is unlocked.

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y			85.65%	R	
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y					
BMI Percentile				33.33%	R	
Counseling for Nutrition				43.29%	R	
Counseling for Physical Activity				41.44%	R	
Childhood Immunization Status (cis)	Y					
DTaP				78.70%	R	
IPV				89.35%	R	
MMR				88.66%	R	
HiB				90.74%	R	
Hepatitis B				84.72%	R	
VZV				90.74%	R	
Pneumococcal Conjugate				80.79%	R	
Hepatitis A				69.91%	R	
Rotavirus				61.81%	R	
Influenza				34.03%	R	
Combination #2				71.99%	R	
Combination #3				70.37%	R	
Combination #4				56.48%	R	
Combination #5				51.39%	R	
Combination #6				27.55%	R	
Combination #7				45.60%	R	
Combination #8				25.93%	R	
Combination #9				21.99%	R	
Combination #10				21.30%	R	
Immunizations for Adolescents (ima)	Y					
Meningococcal				81.99%	R	
Tdap/Td				91.32%	R	
Combination #1				81.03%	R	
Human Papillomavirus Vaccine for Female Adolescents (hpv)	Y			15.28%	R	
Lead Screening in Children (lsc)	Y			68.18%	R	
Breast Cancer Screening (bcs)	Y			NA	R	
Cervical Cancer Screening (ccs)	Y			48.93%	R	
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Y			9.84%	R	
Chlamydia Screening in Women (chl)	Y					
16-20 Years				41.84%	R	
21-24 Years				54.46%	R	
Total				45.56%	R	
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		64.47%	R	
Appropriate Treatment for Children With URI (uri)	Y	Y		59.17%	R	
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		30.45%	R	
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			NA	R	
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
Systemic Corticosteroid				37.13%	R	
Bronchodilator				47.05%	R	
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
5-11 Years				94.79%	R	
12-18 Years				87.72%	R	
19-50 Years				66.67%	R	
51-64 Years				64.74%	R	

Total				85.64%	R	
Medication Management for People With Asthma (mma)	Y	Y				
5-11 Years - Medication Compliance 50%				59.45%	R	
5-11 Years - Medication Compliance 75%				35.14%	R	
12-18 Years - Medication Compliance 50%				57.07%	R	
12-18 Years - Medication Compliance 75%				32.44%	R	
19-50 Years - Medication Compliance 50%				69.18%	R	
19-50 Years - Medication Compliance 75%				43.84%	R	
51-64 Years - Medication Compliance 50%				80.49%	R	
51-64 Years - Medication Compliance 75%				65.04%	R	
Total - Medication Compliance 50%				61.08%	R	
Total - Medication Compliance 75%				37.01%	R	
Asthma Medication Ratio (amr)	Y	Y				
5-11 Years				86.91%	R	
12-18 Years				74.26%	R	
19-50 Years				51.03%	R	
51-64 Years				50.53%	R	
Total				74.22%	R	
Effectiveness of Care: Cardiovascular						
Cholesterol Management for Patients With Cardiovascular Conditions (cmc)	Y					
LDL-C Screening Performed				80.09%	R	
LDL-C Control (<100 mg/dL)				44.21%	R	
Controlling High Blood Pressure (cbp)	Y		N	54.98%	R	
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		71.13%	R	
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y					
Hemoglobin A1c (HbA1c) Testing				88.25%	R	
HbA1c Poor Control (>9.0%)				39.29%	R	
HbA1c Control (<8.0%)				51.04%	R	
HbA1c Control (<7.0%)				39.83%	R	
Eye Exam (Retinal) Performed				35.25%	R	
LDL-C Screening Performed				84.22%	R	
LDL-C Control (<100 mg/dL)				36.75%	R	
Medical Attention for Nephropathy				79.72%	R	
Blood Pressure Control (<140/80 mm Hg)				39.63%	R	
Blood Pressure Control (<140/90 mm Hg)				58.76%	R	
Effectiveness of Care: Musculoskeletal						
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		42.88%	R	
Use of Imaging Studies for Low Back Pain (lbp)	Y			64.20%	R	
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
Effective Acute Phase Treatment				49.86%	R	
Effective Continuation Phase Treatment				33.53%	R	
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
Initiation Phase				64.86%	R	
Continuation and Maintenance (C&M) Phase				74.11%	R	
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
30-Day Follow-Up				61.79%	R	
7-Day Follow-Up				36.07%	R	
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		78.15%	R	
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			71.95%	R	
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			82.35%	R	

Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		64.70%	R	
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
ACE Inhibitors or ARBs				91.28%	R	
Digoxin				91.02%	R	
Diuretics				91.98%	R	
Anticonvulsants				69.76%	R	
Total				89.81%	R	
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
20-44 Years				88.90%	R	
45-64 Years				94.48%	R	
65+ Years				94.51%	R	
Total				91.98%	R	
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
12-24 Months				98.07%	R	
25 Months - 6 Years				93.02%	R	
7-11 Years				97.47%	R	
12-19 Years				96.45%	R	
Annual Dental Visit (adv)	Y	Y				
2-3 Years				43.98%	R	
4-6 Years				72.85%	R	
7-10 Years				72.96%	R	
11-14 Years				67.55%	R	
15-18 Years				60.33%	R	
19-21 Years				42.72%	R	
Total				65.00%	R	
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	Y				
Initiation of AOD Treatment: 13-17 Years				38.04%	R	
Engagement of AOD Treatment: 13-17 Years				19.60%	R	
Initiation of AOD Treatment: 18+ Years				24.62%	R	
Engagement of AOD Treatment: 18+ Years				4.46%	R	
Initiation of AOD Treatment: Total				25.42%	R	
Engagement of AOD Treatment: Total				5.35%	R	
Prenatal and Postpartum Care (ppc)	Y		N			
Timeliness of Prenatal Care				86.54%	R	
Postpartum Care				52.44%	R	
Call Answer Timeliness (cat)	Y			86.80%	R	
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y		N			
<21 Percent				6.03%	R	
21-40 Percent				4.41%	R	
41-60 Percent				4.41%	R	
61-80 Percent				15.55%	R	
81+ Percent				69.61%	R	
Well-Child Visits in the First 15 Months of Life (w15)	Y					
0 Visits				1.62%	R	
1 Visit				0.69%	R	
2 Visits				3.94%	R	
3 Visits				6.25%	R	
4 Visits				8.80%	R	
5 Visits				16.90%	R	
6+ Visits				61.81%	R	
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y			56.31%	R	
Adolescent Well-Care Visits (awc)	Y			43.75%	R	
Frequency of Selected Procedures (fsp)	Y				R	
Ambulatory Care: Total (amba)	Y				R	
Ambulatory Care: Dual Eligibles (ambb)	N				NR	
Ambulatory Care: Disabled (ambc)	N				NR	
Ambulatory Care: Other (ambd)	N				NR	

Inpatient Utilization--General Hospital/Acute Care: Total (ipua)	Y				R	
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	N				NR	
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)	N				NR	
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)	N				NR	
Identification of Alcohol and Other Drug Services: Total (iada)	Y	Y			R	
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N			NR	
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N			NR	
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N			NR	
Mental Health Utilization: Total (mpta)	Y	Y			R	
Mental Health Utilization: Dual Eligibles (mptb)	N	N			NR	
Mental Health Utilization: Disabled (mptc)	N	N			NR	
Mental Health Utilization: Other (mptd)	N	N			NR	
Antibiotic Utilization: Total (abxa)	Y	Y			R	
Antibiotic Utilization: Dual Eligibles (abxb)	N	N			NR	
Antibiotic Utilization: Disabled (abxc)	N	N			NR	
Antibiotic Utilization: Other (abxd)	N	N			NR	
Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	Y				R	
Relative Resource Use for People With Asthma (ras)	Y	Y			R	
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R	
Relative Resource Use for People With Hypertension (rhy)	Y				R	
Relative Resource Use for People With COPD (rco)	Y				R	
Health Plan Descriptive Information						
Board Certification (bcr)	Y				R	
Total Membership (tlm)	Y				R	
Enrollment by Product Line: Total (enpa)	Y				R	
Enrollment by Product Line: Dual Eligibles (enpb)	N				NR	
Enrollment by Product Line: Disabled (enpc)	N				NR	
Enrollment by Product Line: Other (enpd)	N				NR	
Enrollment by State (ebs)	Y				R	
Race/Ethnicity Diversity of Membership (rdm)	Y				R	
Language Diversity of Membership (ldm)	Y				R	
Weeks of Pregnancy at Time of Enrollment (wop)	Y		N		R	